Parkinson’s reversal? One drug brings dying brain cells back to life Stanford researchers discovered that dialing down an overactive enzyme, LRRK2, can regrow lost cellular “antennae” in key brain cells, restoring vital dopamine communication and neuroprotective signals in a mouse model of genetic Parkinson’s. After three months on the LRRK2-blocking drug MLi-2, damaged circuits revived and early signs of neuronal recovery emerged, hinting that timely treatment could not only halt but reverse disease progression—and perhaps benefit other Parkinson’s forms.
https://www.sciencedaily.com/r....eleases/2025/07/2507

Magnesium Deficiency in IBD Patients and the Role of Natural Support When you’re living with a chronic illness like Crohn’s disease or ulcerative colitis, it’s easy to become hyper-aware of every medication, every symptom, and every nutrient—or lack thereof. One essential mineral that often flies under the radar is magnesium. Magnesium supports nerve function, hormone balance and how we respond to stress, so when levels drop, …
https://lightscameracrohns.com..../2025/07/02/magnesiu

Is that really ADHD? Why flawed trials may be misleading millions Researchers reviewing nearly 300 top-tier ADHD drug trials found that half skipped the rigorous, expert-led evaluations needed to rule out other conditions like depression or schizophrenia. With diagnoses often made by unqualified staff—or even by computer—many participants may not have actually had ADHD, casting doubt on study outcomes that shape treatment guidelines.
https://www.sciencedaily.com/r....eleases/2025/07/2507

A midlife MRI that spots rapid aging and signals disease long before symptoms A new brain scan tool shows how quickly your body and mind are aging. It can spot early signs of diseases like dementia, long before symptoms begin. The scan looks at hidden clues in your brain to predict future health.
https://www.sciencedaily.com/r....eleases/2025/07/2507

Brain scan breakthrough reveals why Parkinson’s drugs don’t always work Researchers are using an advanced brain imaging method called MEG to understand why Parkinson’s drug levodopa doesn’t work equally well for everyone. By mapping patients’ brain signals before and after taking the drug, they discovered that it sometimes activates the wrong brain regions, dampening its helpful effects. This breakthrough could pave the way for personalized treatment strategies, ensuring patients receive medications that target the right areas of their brain more effectively.
https://www.sciencedaily.com/r....eleases/2025/06/2506